Delivery Order SPE2DB20D3103-SPE2DB25FP0C0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $24,546.62 to AmerisourceBergen Drug Corp for the supply of Ferumoxytol 510 mg/17 mL vials on October 8, 2025, with an ultimate completion date of October 9, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,652.60 to AmerisourceBergen Drug Corp for the supply of Ferumoxytol 510 mg/17 mL vials. This firm fixed-price, competitively awarded contract was executed on August 22, 2025, with an ultimate completion date of August 25, 2025, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $11,624.29 to AmerisourceBergen Drug Corp for the supply of Ferumoxytol 510 mg/17 mL vials. This contract, awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a firm fixed price delivery order with no set-aside designation. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ferumoxytol 510 mg/17 mL vials, with a ceiling value of $2,702.00 and an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's extensive...
- The Defense Logistics Agency awarded a delivery order valued at $1,391.88 to AmerisourceBergen Drug Corp for the supply of Ferumoxytol 510 mg/17 mL vials on September 19, 2025, with an ultimate completion date of September 22, 2025. This competitively awarded, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ferumoxytol 510 mg/17 mL vials with a contract ceiling value of $10,059.24. This firm fixed-price delivery order, which is set to be completed by August 12, 2025, represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government. The award was made without set-aside restrictions, indicating it was competitively awarded....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,214.82, is a delivery order for the supply of Ferumoxytol 510 mg/17 ml vial, a medical product used for various therapeutic applications. The contract has a firm fixed-price pricing type and a completion date of November 4, 2024. AmerisourceBergen holds a significant Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $6,285.55 to AmerisourceBergen Drug Corp for the supply of Ferumoxytol 510 mg/17 mL vials. This competitively awarded, firm fixed-price contract was executed on August 27, 2025, with an ultimate completion date of August 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ferumoxytol is an intravenous iron replacement therapy used to treat iron deficiency anemia, commonly utilized in...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of Ferumoxytol 510 mg/17 ml vials. The contract, awarded by the Defense Logistics Agency (DLA), is a Firm Fixed Price Delivery Order with a ceiling value of $3,351.60 and a period of performance through February 21, 2025. This contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,405.44, is a Firm Fixed Price delivery order for the supply of 4567887605 - FERUMOXYTOL 510 MG/17 ML VIAL 17ML. The contract has an ultimate completion date of April 14, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP0C0Delivery Order
The Defense Logistics Agency awarded a $25,204.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ferumoxytol 510 mg/17 mL vials, with an ultimate completion date of June 2, 2025. The award was announced on May 30, 2025, and represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $1 billion ceiling and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies an extensive range of pharmaceutical products and medical supplies to defense and veteran healthcare systems. The company holds significant capabilities in fulfilling federal medical supply requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and specialized healthcare commodities. This contract reflects the company's ongoing role as a primary supplier within the DLA's pharmaceutical supply chain and its participation in the broader Pharmaceutical Prime Vendor Global Program, which is designed to leverage multiple contractors across separate regions to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.2k | 5/30/25 |